Dermata Therapeutics, Inc. develops dermatologic solutions and is repositioning its business around direct-to-consumer skincare under the Tome brand. Company updates center on OTC skincare concepts, including once-weekly acne and skin renewal products that use the company's Bioneedle and Spongilla technologies, as well as intellectual-property developments for Bioneedle Delivery System applications involving dermal fillers, botulinum toxin and hyperhidrosis.
Recurring Dermata news also includes financial results, private placements and at-the-market equity activity, along with management, marketing and board developments tied to its shift from pharmaceutical development toward consumer skincare products.
Dermata Therapeutics (DRMA) highlighted editorial coverage of its Tome skincare brand following the commercial launch of its first product. Tome Foundational Treatment launched on August 25, 2026, and received coverage in Women's Wear Daily, Cosmopolitan, AIR MAIL and Thingtesting. Dermata views the exposure as supporting brand awareness and customer acquisition as it expands its direct-to-consumer and professional skincare business.
In October 2026, Dermata announced topline results from a cosmetic clinical study of Tome Foundational Treatment showing improvements across multiple measures of skin appearance. The company expects to launch Tome Clearing Treatment for acne in the first half of 2027. Personal experiences described in the editorial coverage do not establish typical or expected product results.
Dermata Therapeutics (DRMA) enrolled the first participant in a clinical trial evaluating Tome Clearing Treatment, its planned second commercial skincare product. The company expects to launch the once-weekly acne treatment in H1 2027. It combines salicylic acid, an FDA-recognized over-the-counter acne active ingredient, with Dermata's Bioneedle powder.
The open-label study, in which treatment is known, is expected to enroll approximately 24 participants with facial acne. Participants will apply the treatment weekly for 12 weeks, with an optional additional 12 weeks. A dermatologist will assess acne lesion counts, overall acne treatment response and post-inflammatory hyperpigmentation, or dark marks after inflammation. Dermata intends to use the data to support marketing and commercialization. Its first product, Tome Foundational Treatment, is already commercially available.
Dermata Therapeutics (DRMA) announced topline results from a completed cosmetic study evaluating its recently launched Tome Foundational Treatment.
The open-label study, in which treatment was known, included 31 participants who applied the treatment once weekly for four weeks. Investigator assessments covered skin appearance, and participants completed self-evaluations after four treatments. 93% agreed the treatment was comparable to a professional in-office procedure, while 90% agreed they saw more noticeable results compared with other products. No treatment-related adverse events were reported. Tome is Dermata's first commercial product and is available for purchase.
Dermata Therapeutics (Nasdaq: DRMA) announced the commercial launch of the Tome Foundational Treatment, the first product under its Tome direct-to-consumer skincare brand. The once-weekly skin renewal treatment, powered by Dermata’s Bioneedle technology using 100% Spongilla lacustris, is now available for purchase at www.tomeskincare.com as a one-time one-month kit or via discounted monthly subscription.
According to Dermata, this launch marks its transition from a pre-commercial company toward a consumer-focused skincare business and is the first product in a planned portfolio leveraging Bioneedle-based formulations aimed at simplifying skincare routines while improving the appearance of skin tone and texture over time.
Dermata Therapeutics (NASDAQ: DRMA) opened preorders for Tome Foundational Treatment, its first direct-to-consumer skincare product, ahead of an expected commercial launch and initial shipping date of August 25, 2026. The once-weekly topical mask, positioned as a skin "reset," retails for $178 (about $45 per treatment), with a 10% discount for subscribers.
Each four-treatment kit includes Bioneedle™ powder, an Activator tube, and an application brush, mixed by the user immediately before use. According to Dermata, Tome will be the lead brand for a broader planned portfolio of clinically tested, professional-grade, at-home skincare products.
Dermata Therapeutics (NASDAQ: DRMA) entered into definitive agreements for a private placement priced at-the-market under Nasdaq rules, issuing 2,293,608 shares of common stock (or pre-funded warrants) plus series E and short-term series F warrants to purchase up to 4,587,216 additional shares at $1.46 per share and accompanying warrants.
The placement is expected to close on or about August 18, 2026, generating approximately $3.4 million in gross proceeds, with up to about $6.7 million in potential additional gross proceeds if all warrants are exercised for cash. Company insiders, including the CEO and CFO, are participating at a $1.47 purchase and exercise price. According to Dermata Therapeutics, net proceeds will support general corporate purposes, including consumer research, launch activities for its planned August 25, 2026 direct-to-consumer skin renewal product, licensing, potential acquisitions, and working capital. The securities are being issued in a private offering under Section 4(a)(2) and/or Regulation D, with agreed resale registration rights.
Dermata Therapeutics (NASDAQ:DRMA) reported second quarter 2026 results and detailed its pivot to a commercial-stage, direct-to-consumer skincare model centered on its new Tome brand. The company expects to launch its first product, Tome Foundational Treatment, on August 25, 2026, with manufacturing and packaging completed and a social media campaign underway.
As of June 30, 2026, Dermata held $4.4 million in cash and cash equivalents versus $7.5 million at year-end 2025, and expects this to fund operations into Q4 2026. Q2 2026 research and development expenses declined to $0.2 million, while selling, general and administrative expenses rose to $2.8 million driven by higher legal, marketing, commercialization, and reallocated employee costs. Total assets were $5.3 million, equity was $3.5 million, and the company reported a Q2 2026 net loss of $3.0 million, or $(0.74) per share.
Dermata Therapeutics (NASDAQ:DRMA) plans to commercially launch its first direct-to-consumer skincare product, Tome Foundational Treatment, on August 25, 2026, with waitlist customers receiving early preorder access. The once-weekly skin renewal treatment uses Dermata’s proprietary Bioneedle™ technology, based on a wild harvested freshwater sponge, to support at-home skin resurfacing.
The four-treatment Foundational Treatment set will be sold exclusively via tomeskincare.com for $178 (about $45 per treatment) and includes Bioneedle powder, an Activator solution, and an application brush. According to Dermata, this launch marks a strategic pivot toward a consumer-focused, revenue-generating business model and is the first product in a planned Tome portfolio.
Dermata Therapeutics (Nasdaq: DRMA) reported a strategic shift toward direct-to-consumer skincare in Q1 2026, advancing its new Tome brand. The company plans to launch its once-weekly Tome Foundational Treatment in mid-2026 and is preparing a second DTC product.
Dermata raised $2.0 million in net proceeds via its ATM, ending March 31, 2026 with $6.9 million in cash and cash equivalents and expecting funding runway into Q1 2027. Q1 2026 research and development expenses declined to $0.4 million, while selling, general and administrative expenses rose to $1.5 million, reflecting marketing, audit, and legal costs.
Dermata (Nasdaq:DRMA) received notice of acceptance from the Australian Patent Office for Australian Patent Application No. 2020315876, covering topical delivery of dermal fillers using its Bioneedle Delivery System (BDS). The patent will be automatically issued three months after acceptance unless a third party files an opposition.
The acceptance would be Dermata's first patent, if issued, for BDS with dermal fillers and adds to existing allowed and issued BDS patents for botulinum toxin in the US, Australia, and Japan. The company noted a strategic shift to selling direct to skincare professionals.